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Background:  The advent of low-dose helical computed tomogra-
phy for lung cancer screening will likely lead to an increase in the 
detection of stage I lung cancer. Presently, these patients are primar-
ily treated with surgery alone and approximately 30% will develop 
recurrence and die. Biomarkers that can identify patients for whom 
adjuvant chemotherapy would be a benefit could significantly reduce 
both patient morbidity and mortality. Herein, we sought to build a 
prognostic inflammatory–based classifier for stage I lung cancer.
Methods: We performed a retrospective analysis of 548 European 
American lung cancer cases prospectively enrolled in the Prostate, 
Lung, Colorectal and Ovarian study. C-reactive protein, interleu-
kin (IL)-6, IL-8, tumor necrosis factor-α, and IL-1β were measured 
using an ultrasensitive electrochemiluminescence immunoassay in 
serum samples collected at the time of study entry.
Results: IL-6 and IL-8 were each associated with significantly shorter 
survival (hazard ratio [HR], 1.33; 95% confidence interval [CI], 1.08–
1.64; p = 0.007; and HR, 1.3; 95% CI, 1.09–1.67; p = 0.005, respectively). 
Moreover, a combined classifier of IL-6 and IL-8 were significantly asso-
ciated with poor outcome in stage I lung cancer patients (HR, 3.39; 95% 
CI, 1.54–7.48, p = 0.002) and in stage 1 patients with more than or equal 
to 30 pack-years of smoking (HR, 3.15; 95% CI, 1.54–6.46, p = 0.002).
Conclusions: These results further support the association between 
inflammatory markers and lung cancer outcome and suggest that a 
combined serum IL-6/IL-8 classifier could be a useful tool for guid-
ing therapeutic decisions in patients with stage I lung cancer.
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(J Thorac Oncol. 2014;9: 1494–1503)
Lung cancer remains the leading cause of cancer-related mortality in the United States.1 For all stages of lung can-
cer combined, the 5-year survival rates are still less than 17%. 
However, patients diagnosed with stage IA disease and who 
undergo surgery have a 5-year survival rate of approximately 
75%, and this rate decreases to 71% for patients with stage IB 
disease and further declines with increasing stage.1,2 Although 
surgery remains the standard of care for patients with stage I 
lung cancer, between 20% and 30% of patients with histologi-
cally negative lymph nodes at the time of surgery will experi-
ence a recurrence3 and the prospective identification of these 
patients remains a challenge. Biomarkers that can identify 
patients for whom adjuvant chemotherapy would be a benefit 
could significantly reduce both patient morbidity and mortal-
ity. Results from the National Lung Screening Trial indicate 
that annual screens with low-dose helical computed tomog-
raphy (LDCT) can reduce the mortality associated with lung 
cancer by 20%,4 especially those at higher risk.5 The study 
prompted the U.S. Preventative Services Task Force to recom-
mend low-dose computed tomography screening for all indi-
viduals aged between 55 and 80 with a smoking history of 
more than or equal to 30 pack-years.6 The immense sensitivity 
of this imaging tool has led to increased detection of stage I 
lung cancers, thus enhancing the need for biomarker-guided 
approaches to the treatment of stage I lung cancer and the 
prospective identification of patients at risk of tumor recur-
rence. Moreover, a recent study estimates the rate of overdiag-
nosis in the National Lung Screening Trial (NLST) at 18.5%7; 
biomarkers that can be combined with an imaging screening 
program could offer improved prospective identification of 
aggressive and indolent tumors, and thus informed treatment 
of patients with LDCT-detected lung cancer.
We8 and others9–12 have shown an association between 
a systemic inflammatory response and a higher risk of lung 
cancer mortality.9–11,13–15 In addition, chronic inflammatory 
states,16 including chronic obstructive pulmonary disorder 
(COPD)17,18 and asbestosis,19 are associated with a higher 
risk of lung cancer mortality. Inflammatory cells may par-
ticipate in lung carcinogenesis by generating reactive oxygen 
and nitrogen species, by secreting growth stimulatory cyto-
kines, and by contributing to the formation of DNA adducts.20 
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Identifying biomarkers that quantify such signals and pro-
spectively inform cancer prognosis, especially for patients 
with stage I lung cancer, could prove extremely useful in the 
management of lung cancer. However, few studies have exam-
ined the association between chronic inflammation and lung 
cancer survival in patients with stage I disease.
PATIENTS AND METHODS
Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening Trial Study
Participants within the screening arm of the Prostate, 
Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial 
were selected for this nested case-control study as described 
previously.21 The PLCO screening trial was a randomized trial 
designed to evaluate the efficacy of cancer screening in reduc-
ing cancer mortality. It recruited 155,000 men and women aged 
55–74 years from 1992 to 2001, from 10 centers throughout the 
United States.22 Participants in the screening group provided 
blood samples annually for 6 years, but baseline blood samples 
were used in this study. At the time of December 31, 2004, sam-
ple selection cutoff date, 898 lung cancers had been diagnosed 
among the 77,464 participants in the screening group. Patients 
were excluded if they had a missing consent for utilization of 
biological specimens for etiologic studies, missing baseline 
questionnaire, diagnosis of multiple cancers during the study, 
missing smoking information at baseline, or unavailability of 
serum specimens. Patients for whom lung cancer was not the 
primary diagnosis were removed from the analysis as it was 
thought that other cancer types could confound the association. 
For example, if cytokines were high, it could be because they 
later developed a different cancer that is preceded by elevated lev-
els. This point is relevant given our previous work showing that 
serum levels of a biomarker can be elevated many years before 
a cancer diagnosis.21 Five hundred forty-eight serum samples 
from European American and 44 serum samples from African 
American patients with lung cancer were available. This propor-
tion was comparable to the enrollment of African Americans in 
the full PLCO trial (6%).23 The characteristics of the European 
American cases included in this study are described in Table 1.
Death from lung cancer was initially determined through 
a questionnaire that was distributed annually by mail and link-
age to the National Death Index. Subsequently, a death review 
panel confirmed the cause of death in a uniform unbiased man-
ner. Further details outlining this process are described.24 Tumor, 
node, metastasis stage was initially determined using the fifth 
edition of the American Joint Committee on Cancer’s Cancer 
Staging Manual. Stage was subsequently reclassified using the 
tumor, node, metastasis criteria, seventh edition.25 Death certifi-
cates were obtained to confirm death and to determine cause of 
death. Lung cancer-specific death was defined as one with an 
underlying cause of lung cancer or treatment for lung cancer.
Measurement of Inflammatory Markers
Serum cytokines were determined in a previous study.21 
Data on prognosis were not assessed at the time of this study 
as survival data for participants in the lung screening portion 
of PLCO had not yet been analyzed and the data were not 
available. Since then, it has been shown that annual screening 
with chest radiograph does not reduce lung cancer mortality 
compared with usual care.26 Briefly, sera from T0 (or the earliest 
time point available) were retrospectively tested for circulating 
levels of CRP, interleukin (IL)-6, IL-8, IL-1β, and tumor necro-
sis factor (TNF)-α. IL-6, IL-8, IL-1β, and TNF-α levels were 
measured using an ultrasensitive 4-Plex kit. CRP was measured 
as reported earlier.27 Briefly, 10-µL serum were measured for 
CRP using the Immulite 1000 High Sensitivity CRP chemilu-
minescent immunometric assay and instrumentation (Siemens 
Medical Solutions Diagnostics, Los Angeles, CA), following 
the manufacturer’s protocol. Samples were blinded and ran-
domly distributed. All samples were assayed in duplicate; results 
shown are based on the average of those duplicates. Controls 
and standard curves were included with each plate, and as an 
added quality control, 12% of the samples from all three studies 
were blindly duplicated and evenly distributed both interplate 
and intraplate. The interplate correlations for IL-6 and IL-8 
were 0.78 and 0.76, respectively. Intraplate correlations for 
IL-6 and IL-8 were 0.84 and 0.92, respectively.21 Samples with 
values lower than the detection limit were assigned a value of 
one-half of the detection limit. The detection limit for each plate 
was determined based on linearity of the standard curve fol-
lowing the manufacturer’s instructions. As reported previously, 
the average limit of detection for IL-6 was 0.11 and 0.10 pg/ml 
for IL-8 in this study.21 For both IL-6 and IL-8, there were no 
samples that fell below this detection limit. The limit of detec-
tion for CRP was 0.2 µg/ml, samples below this detection limit 
were assigned a level of 0.2 µg/ml. For this study, there were 
no samples that fell below this detection limit. Quartiles (25%, 
50%, and 75%) were based on serum IL-6 and IL-8 cutoff lev-
els among European American controls in our previous study 
(IL-6, 1.4, 2.1, 3.8 pg/ml; IL-8, 7.0, 10.8, 28.5 pg/ml).21 Median 
and quartile levels of IL-1β, CRP, and TNF-α are outlined in 
Table 1. These cutoff values were also determined based on the 
European American controls of our previous study.
Statistical Analysis
To test the magnitude of association between inflammatory 
markers with lung cancer-specific survival, hazard ratios (HR) 
were estimated using multivariable Cox proportional hazards 
regression modeling28 with adjustment for potential confounders, 
including age (continuous), sex (male/female), current smok-
ing status (never/former/current), stage (stage I/stage II/stage 
III/stage IV), histology (adenocarcinoma, squamous cell carci-
noma, and other), and pack-years of smoking. The 44 African 
American samples were removed from our analysis as numbers 
were too small for a stratified analysis. Time from lung can-
cer diagnosis was used to estimate the survival timescale, and 
failure was described as lung cancer-specific death. Statistical 
analyses were performed using STATA (Version 12, StataCorp, 
College Station, TX). Proportional hazards assumptions were 
verified by visual inspection of log-log plots and using a nonzero 
slope test of the Schoenfeld residuals29 (p = 0.754 for all stages, 
p = 0.257 stage I, and p = 0.525 stage I and ≥30 pack-years 
of smoking). Our results were analyzed and presented accord-
ing to the Reporting Recommendations for Tumor Markers 
(REMARK) guidelines.30,31 In this study, causes of death other 
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TABLE 1.  Distribution of Characteristics Among the Prostate, Lung, Colorectal and Ovarian Lung Cancer Cases 
Included in Our Study
Characteristic n %
IL-6 Stage I Only IL-8 Stage I Only
Median (IQR) Median (IQR)
n 548 100 164 164
Age (yr), mean ± SD (range) 65 ± 5 (55–74)
Race
  White, non-Hispanic 548 100 4.1 (2.7–7.3) 19.1 (13.9–24.1)
  Black, non-Hispanic
  Hispanic
  Asian
  Pacific Islander/American Indian
Sex
  Male 370 67.5 4.6 (2.7–8.2) 19.0 (14.2–24.0)
  Female 178 32.5 3.8 (2.8–5.7) 19.1 (13.3–24.2)
Smoking status
  Never 38 6.9 3.9 (2.8–4.8) 15.2 (11.5–20.5)
  Former 214 39.1 4.3 (2.6–8.0) 19.2 (15.0–24.2)
  Current 296 54.0 4.1 (2.8–7.8) 18.6 (12.1–24.0)
Pack-years, mean SD (range) 56.6 ± 35.9 (0–230)
Family history of cancer
  No 419 18.8 4.3 (2.7–7.2) 19.1 (13.8–24.2)
  Yes 97 81.2 3.3 (2.7–5.7) 19.3 (15.0–23.2)
  Missing 32
Stage
  Ia 104 22.9
  Ib 60 13.2
  II 36 7.9
  III 73 16.1
  IV 171 39.9
  Missing 94
Histology
  Adenocarcinoma 175 22.9 3.9 (2.4–6.3) 18.0 (13.8–23.2)
  Squamous cell carcinoma 121 22.1 5.7 (3.3–8.4) 21.5 (17–24.2)
  Small cell carcinoma 70 12.8 NA NA
  Bronchoalveolar adenocarcinoma 48 8.8 3.1 (2.6–4.4) 15.9 (11.7–22.7)
  Large cell carcinoma 33 6.0 6.6 (2.9–6.7) 17.7 (9.4–29.3)
  Other 96 17.5 3.5 (2.8–7.0) 19.1 (12.1–24.2)
  Missing 5
IL-6
  Median (IQR) 4.4 (2.9–7.2 pg/ml)
IL-8
  Median (IQR) 18.9 (14.0–24.8 pg/ml)
Tumor necrosis factor-α
  Median (IQR) 9.5 (7.6–12.3 pg/ml)
IL-1β
  Median (IQR) 0.8 (0.5–1.4 pg/ml)
CRP
  Median (IQR) 3.5 (1.5–7.9 pg/ml)
Arthritis
  No 321 58.0 3.7 (2.6–6.6) 19.2 (14.2–24.2)
  Yes 228 42.0 4.8 (3.0–8.1) 19.1 (11.8–24.7)
(Continued)
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than lung cancer were censored. There were 29 individuals (5.3%) 
whose cause of death was not lung cancer. Of these, 19 (11.2%) 
were in the stage I category. As competing risks are distinct from 
standard censoring, we performed a competing risks regression 
based on the method of Fine and Gray32 using the stcrreg function 
in STATA. A new variable was generated to specify the compet-
ing events (death from cancer and death from another cause).
RESULTS
Increased Serum Levels of IL-6 and 
IL-8 Are Associated With a Higher 
Risk of Lung Cancer Mortality
The participants with lung cancer in this study had a 
median survival time from diagnosis of 1.3 years. For patients 
with stage I cancer, the median survival time increased to 6.1 
years. Increasing levels of IL-1β (HR, 1.09; 95% confidence 
interval [CI], 0.98–1.21; p
trend
 = 0.119), CRP (HR, 1.06; 95% 
CI, 0.95–1.18; p
trend
 = 0.231), and TNF-α (HR, 1.09; 95% CI, 
0.99–1.19; p
trend
 = 0.077) were not associated with risk of lung 
cancer mortality (Supplementary Table 1, Supplementary 
Digital Content 1, http://links.lww.com/JTO/A636). Increased 
IL-6 levels, categorized based on the median or quartiles, were 
associated with a higher risk of mortality (HR≥
median versus <median
, 
1.33; 95% CI, 1.08–1.64; p = 0.007) (Supplementary Table 1, 
Supplementary Digital Content 1, http://links.lww.com/JTO/
A636) (Table 2). In addition, high levels of IL-8, categorized 
as above the 75th percentile, were also associated with higher 
risk of death (HR≥
75th percentile versus <75th percentile
, 1.43; 95% CI, 
1.13–1.80; p = 0.002). As certain health conditions associated 
with systemic inflammation were recorded as part of the ques-
tionnaires in PLCO, we also adjusted our analyses for chronic 
bronchitis (no/yes), emphysema (no/yes), arthritis (no/yes), 
body mass index at baseline (0–18.5/18.5–25/25–30/30+), and 
diabetes (no/yes). Controlling for these potential confounders 
did not change the magnitude of the association between IL-6 
(HR≥
median versus <median
, 1.32; 95% CI, 1.05–1.66; p = 0.017) and 
IL-8 (HR≥
75th percentile versus <75th percentile
, 1.39; 95% CI, 1.10–1.76; 
p = 0.006) with lung cancer survival. In addition, there was 
no significant difference in IL-6 or IL-8 levels among patients 
with and without these conditions, with two exceptions; IL-6 
levels were higher in patients with both emphysema and 
chronic bronchitis (Table 1).
Association of Circulating IL-6 and IL-8 
With Outcome of Stage I Lung Cancer
Results from the NLST show that annual screens of 
high-risk individuals with LDCT reduces lung cancer mor-
tality and diagnoses a predominance of early-stage lung can-
cer, particularly stage 1A.4,5 Thus, given the need for robust 
prognostic biomarkers for stage I lung cancer, we conducted 
a subgroup analysis and restricted our cases to those diag-
nosed with stage I disease (36% of patients in our study). We 
observed that increased levels of both IL-6 and IL-8 were 
associated with an increased risk of mortality in this group 
(Table 3): IL-6 (HR≥
median versus <median
, 2.19; 95% CI, 1.23–3.81; 
p = 0.006) (Table 3) and IL-8 (HR≥
75th percentile versus <75th percentile
, 
1.85; 95% CI, 1.12–3.04; p = 0.016). Additional control-
ling for inflammatory health conditions did not signifi-
cantly alter the magnitude of the association between IL-6 
(HR≥
median versus <median
, 2.05; 95% CI, 1.13–3.72; p = 0.018) 
and IL-8 (HR≥
75th percentile versus <75th percentile
, 1.83; 95% CI, 1.05–
3.21; p = 0.034) with lung cancer survival. Levels of TNF-
α, IL-1β, or CRP were not associated with outcome of 
stage I lung cancer (Supplementary Table 2, Supplementary 
Digital Content 1, http://links.lww.com/JTO/A636).
Selection criteria for LDCT included high-risk individ-
uals with at least 30 pack-years of smoking; therefore, we also 
Emphysema
  No 486 88.0 3.9 (2.7–7.0)a 18.6 (13.8–24.2)
  Yes 65 12.0 7.1 (4–10.25) 21.7 (17.6–21.1)
Chronic bronchitis
  No 489 89.0 3.8 (2.7–7.0)a 18.6 (13.8–23.5)
  Yes 62 11.0 7.2 (4.4–9.1) 22.1 (19.1–25.3)
Diabetes
  No 502 91 3.8 (2.7–7.2) 19.2 (14.0–24.2)
  Yes 48 9 4.7 (4.3–5.7) 15.8 (14.0–20.4)
Body mass index at baseline
  <18.5 kg/m2 5 1.0 7.2 (7.2–7.2) 24.2 (24.2–24.2)
  18.5–25 kg/m2 198 36.0 3.6 (2.6–7.8) 21.5 (15.5–25.4)
  25–30 kg/m2 146 45.0 4.1 (2.7–7.0) 17.4 (13.3–21.9)
  >30 kg/m2 98 18.0 4.7 (3.0–8.2) 18.6 (12.1–21.2)
Survival (yr), mean ± SD (range) 3.1 ± 3.6 (0–12.8)
ap < 0.05.
IL, interleukin; IQR, interquartile range; NA, not applicable.
TABLE 1. (Continued)
Characteristic n %
IL-6 Stage I Only IL-8 Stage I Only
Median (IQR) Median (IQR)
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conducted a stratified analysis by high and low pack-years of 
smoking (<30 versus ≥30) to determine whether circulating 
levels of IL-6 and IL-8 remained significantly associated with 
risk of mortality in this population. IL-6 levels higher than the 
median (HR
pack-years < 30
, 1.60; 95% CI, 0.78–3.27; p = 0.198; 
n = 89) (HR
pack-years ≥ 30, 2.16; 95% CI, 1.13–4.15; p = 0.020; 
n = 127), and IL-8 levels greater than the 75th percentile 
(HR
pack-years < 30
, 1.06; 95% CI, 0.21–5.40; p = 0.946; n = 39) 
(HR
pack-years ≥ 30, 1.92; 95% CI, 1.07–3.44; p = 0.028; n = 127) 
were both significantly associated with a higher risk of lung 
cancer mortality in stage I patients with more than 30 pack-
years of smoking. Levels of TNF-α, IL-1β, or CRP were not 
associated with outcome of stage I lung cancer among patients 
with more than 30 pack-years of smoking (Supplementary 
Table 3, Supplementary Digital Content 1, http://links.lww.
com/JTO/A636).
A Combined IL-8 and IL-6 Classifier Is 
Prognostic for Stage I Lung Cancer
Biomarkers, when used alone, can misclassify some 
patients. However, combining two or more biomarkers 
together is likely to reduce this level of misclassification and 
therefore increase the accuracy of the prediction. For this to 
work, however, the biomarkers should be independent of 
each other. As the association between IL-8 with lung cancer 
prognosis was independent of IL-6 in the multivariable model 
(Table 2), we reasoned that combining IL-8 and IL-6 into a 
single classifier could be more predictive of survival than 
either marker alone. Therefore, we created the following vari-
able: 0 (IL-6 < median and IL-8 < 75th percentile), 1 (IL-6 
≥ median and IL-8 < 75th percentile or IL-6 < median and 
IL-8 ≥ 75th percentile) and 2 (IL-6 ≥ median and IL-8 ≥ 75th 
percentile). In patients with stage I lung cancer, those with 
both high IL-8 and high IL-6 levels has significantly higher 
risk of lung cancer-specific death than those with low levels 
(HR
High IL-6/High IL-8 versus Low IL-6/Low IL-8
, 3.14; 95% CI, 1.50–6.60; p = 
0.002; n = 166) (Fig. 1) (Table 4). At 5 years, 73% of stage 1 
patients with low levels of IL-8 and IL-6 were alive, compared 
with 46% of patients with high levels of IL-6 and IL-8 (Fig. 1).
As mentioned, there were 29 individuals who died 
from a cause of death other than lung cancer. A competing 
risks survival analysis indicated that the association between 
the IL-6/IL-8 classifier with outcome was not affected by 
censoring of the 29 individuals who died of causes other 
than lung cancer (HR
High IL-6/High IL-8 versus Low IL-6/Low IL-8
, 1.78; 
95% CI, 1.32–2.41; p < 0.0001). This was also true for stage 
I lung cancer (HR
High IL-6/High IL-8 versus Low IL-6/Low IL-8
, 3.18; 95% 
CI, 1.59–6.39; p = 0.001).
The combined IL-8/IL-6 classifier was associated 
with outcome of stage I lung cancer among current smok-
ers (Supplementary Table 4, Supplementary Digital Content 
TABLE 2.  Circulating Serum IL-6 and IL-8 Associated With Risk of Lung Cancer Mortality in Prostate, Lung, Colorectal and 
Ovarian (European American Only)
n
Univariable Multivariablea
HR 95% CI p HR 95% CI p
IL-6de
  First quartile 97 Reference Reference Reference Reference
  Second quartile 136 1.39 1.03–1.88 0.034 1.30 0.93–1.81 0.129
  Third quartile 147 1.53 1.14–2.06 0.004 1.48 1.07–2.06 0.019
  Fourth quartile 168 1.73 1.30–2.31 <0.0001 1.64 1.19–2.25 0.002
  p
trend
1.18 1.08–1.25 <0.0001 1.16 1.06–1.28 0.002
  ≤Median 243 Reference Reference Reference Reference
  >Median 305 1.28 1.07–1.55 0.008 1.33 1.08–1.64 0.007
1.28 1.03–1.58 0.023b
IL-8de
  First quartile 111 Reference Reference Reference Reference
  Second quartile 122 1.00 0.74–1.36 0.993 1.12 0.78–1.58 0.539
  Third quartile 147 0.97 0.72–1.30 0.832 0.94 0.69–1.32 0.724
  Fourth quartile 168 1.19 0.90–1.58 0.223 1.37 0.99–1.89 0.057
  p
trend
1.06 0.97–1.16) 0.221 1.09 0.99–1.21 0.093
  ≤75th percentile 375 Reference Reference Reference Reference
  >75th percentile 173 1.23 1.00–1.52 0.047 1.43 1.13–1.80 0.002
1.38 1.10–1.74 0.006c
Bold indicates statistical significance.
aAdjusted for age, sex, stage, histology, and smoking status.
bAdjusted for age, sex, stage, histology, smoking status, and IL-8.
cAdjusted for age, sex, stage, histology, smoking status, and IL-6.
dQuartiles (25%, 50%, and 75%) were based on serum IL-6 and IL-8 cutoff levels among controls in the National Cancer Institute-Maryland (NCI-MD) study (IL-6, 1.4, 2.1, 3.8 
pg/ml; IL-8 7.0, 10.8, and 28.5 pg/ml).
eSerum IL-6 and IL-8 levels were dichotomized into ≤ the median vs. > the median among controls in the NCI-MD study (IL-6, 2.1 pg/ml; IL-8 10.8 pg/ml).
IL, interleukin; HR, hazard ratio; CI, confidence interval.
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1, http://links.lww.com/JTO/A636). Furthermore, restricting 
the analysis to stage I patients with more than or equal to 30 
pack-years of cigarettes, we again found that the classifier 
was specifically associated with higher risk of mortality in 
this subgroup (HRHigh IL-6/High IL-8 versus Low IL-6/Low IL-8, 3.58; 95% CI, 
1.59–8.08; p = 0.002; n = 127) (Table 4). Additional adjustments 
for potential confounding by past or prevalent chronic inflamma-
tory conditions (HRHigh IL-6/High IL-8 versus Low IL-6/Low IL-8, 3.58; 95% CI, 
1.59–8.08; p = 0.002; n = 125) or body mass index at diagnosis, 
at age 20, and at age 50 (HRHigh IL-6/High IL-8 versus Low IL-6/Low IL-8, 3.27; 
95% CI, 1.39–7.73; p = 0.007; n = 121) did not alter the associa-
tions. To rule out the possibility that most stage I lung cancers 
were diagnosed close to serum collection, we also adjusted our 
model for the time interval between serum collection and lung 
cancer diagnosis; however, our association remained statisti-
cally significant (HRHigh IL-6/High IL-8 versus Low IL-6/Low IL-8, 3.16; 95% CI, 
1.54–6.47; p = 0.002; n = 166). Moreover, as our samples 
were taken at study entry, and not the exact time of diagnosis, 
we also tested the temporality of the prognostic signal in our 
samples. This is important, as were IL-8 and IL-6 to be used 
as a prognostic classifier in the clinic, it would be important 
to know if the association with prognosis is evident in sam-
ples taken around the time of diagnosis or whether the signal 
extends further back in time. For both cytokines, the signals 
were predominantly observed in samples taken approxi-
mately 3 months before diagnosis (Supplementary Table 5, 
Supplementary Digital Content 1, http://links.lww.com/JTO/
A636). For IL-6, an association with prognosis was also evi-
dent 1–3 years before diagnosis.
For patients with stage IA lung cancer, chemotherapy 
and radiation are not usually recommended; however, adjuvant 
treatment may be indicated for patients with stage IB lung can-
cer.33 We therefore refined our analysis further to look at the 
strength of the IL-8 and IL-6 classifier in stage IA (n = 104) 
and stage IB (n = 60) lung cancer. As shown in Figure 1B, C, 
we found that patients with high levels of both IL-6 and IL-8 
had significantly shorter survival times compared with those 
with low IL-6 and IL-8. In patients with stage IA lung cancer, 
although they will most likely have received surgery and not 
chemotherapy,33 the combined IL-6/IL-8 classifier was signifi-
cantly associated with outcome (HRhigh for one versus low for both, 3.23; 
95% CI, 1.07–9.74; p = 0.038; HRhigh for both versus low for both, 6.27; 
95% CI, 1.95–20.20; p = 0.002). However, it will be important 
in the future as newer therapeutic options evolve to carry out 
studies that examine if, and how, radiation and chemotherapy 
influence the association between these cytokines and outcome.
Lung cancer is primarily classified into four main histo-
logical subtypes: adenocarcinoma, squamous cell carcinoma, 
large cell carcinoma, and small cell carcinoma. These share a 
common etiologic cause (i.e., tobacco) but also some distinct 
features and association with prognosis.34 We therefore tested 
the association between the IL-6/IL-8 classifier with risk of 
TABLE 3.  Circulating Serum IL-6 and IL-8 Associated With Risk of Lung Cancer Mortality in Stage I Diagnosed Lung Cancer 
(European American Only)
Univariable Multivariablea
HR 95% CI p HR 95% CI p
IL-6de
  First quartile Reference Reference Reference Reference
  Second quartile 0.99 0.38–2.56 0.981 1.06 0.41–2.75 0.908
  Third quartile 1.93 0.84–4.44 0.122 1.98 0.85–4.60 0.111
  Fourth quartile 3.18 1.46–4.44 0.004 2.88 1.31–6.35 0.009
  p
trend
1.57 1.23–2.00 <0.0001 1.47 1.16–1.89 0.002
  ≤Median Reference Reference Reference Reference
  >Median 2.41 1.40–4.14 0.002 2.19 1.23–3.81 0.006
2.02 1.16–3.54 0.014b
IL-8de
  First quartile Reference Reference Reference Reference
  Second quartile 1.41 0.62–3.22 0.418 1.5 0.64–3.48 0.350
  Third quartile 1.04 0.45–2.41 0.925 1.12 0.49–2.60 0.787
  Fourth quartile 2.09 0.98–4.45 0.056 2.22 1.04–4.74 0.039
  p
trend
1.24 0.99–1.57 0.067 1.27 1.00–1.60 0.048
  ≤75th percentile Reference Reference Reference Reference
  >75th percentile 1.82 1.11–2.99 0.018 1.85 1.12–3.04 0.016
1.60 0.96–2.66 0.069c
Bold indicates statistical significance.
aAdjusted for age, sex, stage, histology, and smoking status.
bAdjusted for age, sex, stage, histology, smoking status, and IL-8.
cAdjusted for age, sex, stage, histology, smoking status, and IL-6.
dQuartiles (25%, 50%, and 75%) were based on serum IL-6 and IL-8 cutoff levels among controls in the National Cancer Institute-Maryland (NCI-MD) study (IL-6, 1.4, 2.1, and 
3.8 pg/ml; IL-8 7.0, 10.8, and 28.5 pg/ml).
eSerum IL-6 and IL-8 levels were dichotomized into ≤ the median vs. > the median among controls in the NCI-MD study (IL-6, 2.1 pg/ml; IL-8, 10.8 pg/ml).
IL, interleukin; HR, hazard ratio; CI, confidence interval.
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mortality from each histological subtype of lung cancer. As 
shown in Supplementary Table 6 (Supplementary Digital 
Content 1, http://links.lww.com/JTO/A636), the IL-6/IL-8 
classifier was significantly associated with poor outcome of 
adenocarcinoma (HR, 1.21; 95% CI, 1.02–1.43). Although 
a similar trend was observed for squamous cell carcinoma, 
it was not significant. The IL-6 and IL-8 classifier was not 
associated with outcome of large cell or small cell carcinoma. 
However, the power to detect associations in subgroups is less. 
Levels of IL-6 and IL-8 did not significantly vary across the 
tumor subtypes (Table 1).
We then assessed whether the IL-8/IL-6 classifier was 
associated with lung cancer outcome in patients who were 
diagnosed by radiograph, post screening, or between screens. 
As mentioned, this study only included patients from the 
screening arm of PLCO, and therefore, there were no cases 
diagnosed from the nonscreened arm of the study. There 
were 181 cases diagnosed by radiograph and 295 clinically 
diagnosed cases (189 of which were diagnosed postscreen-
ing and 96 that were diagnosed between screens). High lev-
els of IL-8 and IL-6 were associated with poor outcome in 
patients whose lung cancer was diagnosed by radiograph 
(HRHigh for both versus Low for both, 1.81; 1.09–3.01; p = 0.022) and in 
the postscreening period (HRHigh for both versus Low for both, 3.01, 1.38–
3.15; p = 0.003). However, the classifier was not associated 
with lung cancer in patients whose cancers were diagnosed 
between screens (HRHigh for both versus Low for both, 1.42; 0.71–2.82; 
p = 0.323) (Supplementary Table 7, Supplementary Digital 
FIgURE 1.  Kaplan-Meier curves illustrating the sur-
vival times for patients with stage I (A), stage IA (B), 
and stage IB (C) lung cancer in the prostate, lung, 
colorectal and ovarian cancer screening trial.
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Content 1, http://links.lww.com/JTO/A636). Similar results 
were observed for stage I cancer, although power was reduced.
DISCUSSION
We previously reported that an 11 gene inflamma-
tory messenger RNA (mRNA) expression classifier, which 
included IL-6 and IL-8, was associated with lung cancer out-
come.35 The classifier was derived from mRNA expression 
ratios of tumor and matched nontumor lung tissue. Here, we 
present data that this prognostic mRNA signal is systemi-
cally represented at the protein level in serum, a more readily 
accessible biospecimen. Furthermore, in line with our previ-
ous results with mRNA, we show that combining serum lev-
els of IL-6 with IL-8 gives superior prognostic information 
compared with these markers alone. Some prospective studies 
have also found associations between circulating cytokines 
with lung cancer outcome,9,10,12 but few have investigated the 
association between circulating inflammatory markers and 
lung cancer survival in stage I disease. Our analyses were not 
corrected for multiple comparisons; however, the possibility 
for false discovery is reduced by the fact that it confirms other 
studies.8,36 The NLST results suggest that focus on this group 
of patients will become increasingly important as this success-
ful screening modality diagnoses a majority of stage I disease. 
Several lines of evidence suggest that the systemic 
inflammatory signal emanates from the tumor itself. In addi-
tion to studies that show lung cancer cells express higher lev-
els of IL-8 and IL-6,35,37 numerous studies have also shown 
that inflammatory cytokines, including IL-6 and IL-8, and 
free radicals38 play a direct role in lung carcinogenesis.39–42 
Prevalent inflammatory disorders could confound inflam-
matory signals relating to tumor incidence and outcome; 
however, our analyses were independent of past or prevalent 
inflammatory disorders. They were also independent of smok-
ing, which is again important given that smoking can increase 
levels of IL-6 and IL-8 and the fact that smoking has been 
associated with poor survival.5,43,44
Potential limitations of our work include a restricted 
analysis to a subgroup of inflammatory markers. However, 
given the study design and assay matrix geometry, we were 
limited to this number. Recent studies have suggested that an 
expanded cytokine profile might also be predictive of outcome 
in lung cancer12 and an expanded profile could therefore be 
studied further. Studies of circulating cytokines are open to 
confounding by prevalent systemic inflammatory conditions, 
and while we adjusted for a number of these in our analysis, 
it is possible that other conditions, such as asthma and COPD, 
could have confounded our results. Additional studies should 
aim to additionally control for these conditions.
In light of a series of studies that now show circulat-
ing serum cytokines are associated with lung cancer progno-
sis, several questions and directions remain to be explored. 
For example, our analysis was based on a cutoff derived from 
European American controls in our previous study. Whether 
or not these are the most apt and informative concentrations 
in the larger population remains to be determined. In addition, 
studies will be needed to determine whether IL-8 and IL-6 
are uniformly associated with prognosis in populations across 
geographical regions; analysis of recent data suggests that 
they may not be.8,45–48 Moreover, selection of the appropriate 
biofluid, such as serum versus plasma, may also be an impor-
tant choice.49 Further follow-up studies will also be required 
to define whether circulating inflammatory markers could be 
used as an early marker of tumor recurrence. This is not just an 
unmet need in the clinical management of lung cancer, but one 
where IL-6 and IL-8 could be particularly useful. Our recent 
data showed that IL-6 and IL-8 expression in lung cancer tis-
sue is higher than in nontumor tissue.35 We recently reported 
that increased levels of circulating IL-8 were predictive of lung 
cancer up to 5 years before clinical diagnosis and that circulat-
ing levels of IL-6 are associated with lung cancer diagnosis.21 
These results, and recent work from animal models of cancer 
showing elevated serum levels of IL-6 and vascular endothe-
lial growth factor coincident with tumor recurrence, suggest 
that monitoring cytokines in the circulation could be an effec-
tive means of following tumor relapse. Another factor that will 
need to be refined in larger studies is whether or not this cyto-
kine profile, or indeed whether an alternative one, is prognostic 
of outcome from adenocarcinoma, squamous cell carcinoma, 
and small cell or large cell carcinoma. The data in this study 
suggest that the association is strongest of adenocarcinoma.
Uncertainty remains with regard to how patients with 
stage 1B lung cancer should be treated50–52; some studies 
suggest that patients with stage IB lung cancer should be 
given postoperative adjuvant chemotherapy53,54 while others 
do not.55–57 Although we had limited power, we conducted 
a separate analysis for patients with stage 1A and stage 1B 
lung cancer. We found that 54% of patients with low levels 
TABLE 4.  Risk of Lung Cancer Mortality and an IL-8/IL-6 Signature in Patients with Stage 1 Lung Cancer Stratified by Pack-
Years of Smoking
All <30 Pack-Years of Smoking ≥30 Pack-Years of Smoking
HR 95% CI p HR 95% CI p HR 95% CI p
Low for both Reference Reference Reference
High for one 1.58 0.78–3.14 0.192 1.57 0.85–2.89 0.151 1.39 0.63–3.04 0.411
High for both 3.14 1.50–6.60 0.002 2.4 1.23–4.68 0.996 3.58 1.59–8.08 0.002
p
trend
1.78 1.22–2.60 0.003 1.19 0.46–3.07 0.723 1.95 1.27–3.00 0.002
Data adjusted for age, sex, histology, body mass index, bronchitis, emphysema, and arthritis. Low IL-6 (≤1.4 pg/ml); high IL-6 (>1.4 pg/ml); low IL-8 (≤28.5 pg/ml); and high 
IL-8 (>28.5 pg/ml).
IL, interleukin; HR, hazard ratio; CI, confidence interval.
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of IL-6 and IL-8 were alive after 5 years, compared with 
only 38% of patients with high levels of both cytokines. At 
10 years, the difference in survival was more pronounced; 
20% of stage IB patients with low levels of IL-6 and IL-8 
were alive, compared with only 8% of patients with high 
levels of these cytokines. Moreover, the risk of mortality in 
the 104 patients with stage IA lung cancer, who are more 
likely to receive surgery without further chemotherapy, was 
as follows: HRhigh for one versus low for both, 3.23; 95% CI, 1.07–9.74; 
p = 0.038 and HRhigh for both versus low for both, 6.27; 95% CI, 1.95–
20.20; p = 0.002. Patients with stage IB lung cancer some-
times undergo chemotherapy, although long-term evidence 
that this provides a patient benefit is contradictory. Although 
these data are preliminary, it suggests that further study of 
patients with stage 1B lung cancer should be carried out 
to further define the prognostic utility of these markers. 
Furthermore, analyses that include the treatment regimens 
these patients underwent would be additionally informative.
In summary, we have shown that a combined IL-6 and 
IL-8 classifier is associated with outcome in stage I lung can-
cer in a prospective study with up to 13 years of follow-up. 
Our work confirms our previous findings8 and extends that of 
others.12,36 Sufficient evidence now exists to begin to refine the 
association between these markers with clinical outcome and 
to ascertain both the scope, and limitations, of these mark-
ers in the clinical setting. In addition, given the specific rela-
tionship between these markers with outcome of stage I lung 
cancer in heavy smokers, the potential use of these markers 
within a screening setting, such as that with LDCT, should 
be explored. This is important, as recent studies suggest that 
screen-detected lung cancers may have a different natural his-
tory from that of clinically detected lung cancer,58,59 and there 
is a pressing need to address the consequences associated with 
overdiagnosis of screen-detected lung cancer.7 Our subgroup 
analysis of radiograph versus clinically diagnosed lung cancer 
did not suggest that there was a difference between these two 
groups, but this will have to be confirmed for LDCT-detected 
lung cancer. Analyses of this, and other, promising prognos-
tic classifiers should be explored within such a trial to con-
firm their utility and potential for improving health outcomes 
among patients with lung cancer.
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